Fenwick represented Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood draw, in its $270 million Series C financing, bringing the company's total financing to over $500 million since its launch. The financing was led by new investor Bain Capital Life Sciences and existing investor Perceptive Advisors.
The proceeds will be used to accelerate the PREEMPT CRC clinical trial for Freenome’s blood test for colorectal cancer screening and precancerous lesion detection, advance a pipeline of blood tests for both the early detection and early intervention of additional cancers, and continue building the company’s proprietary multiomics platform.
More information can be obtained from Freenome’s announcement.
The Fenwick transaction team included corporate partner Michael Esquivel and associates Patrick Grilli, Caroline Wells, Jenna Hsieh and R. Harrison Dilday.